Seres Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Seres Therapeutics, Inc. (MCRB) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income0.14-113.72-250.16-65.58-89.13-70.28-98.94
Depreciation & Amortization14.676.246.635.957.587.717.86
Stock Based Compensation20.9734.1025.4820.228.820.000.00
Change in Working Capital-65.51-58.98-18.3941.53-16.56-20.4211.80
Change in Accounts Receivable6.61-8.670.009.39-7.600.000.00
Change in Inventory-33.80-29.650.000.000.000.000.00
Change in Accounts Payable-2.94-11.582.209.36-1.160.000.00
Change in Other Working Capital-31.2615.17-13.474.07-2.870.000.00
Other Operating Activities22.8415.176.234.074.506.36-0.21
Net Cash from Operating Activities-148.61-117.35-228.826.69-93.61-76.52-62.85
Investing Activities
Capital Expenditures-0.38-7.98-9.82-9.570.591.00-1.94
Purchases of Investments13.52-4.4392.25-95.97-158.300.000.00
Sales/Maturities of Investments142.6722.9892.25169.63-158.30-29.52114.26
Other Investing Activities1.400.000.000.000.000.000.00
Net Cash from Investing Activities142.2910.5882.4364.09-158.89-30.52112.32
Financing Activities
Debt Repayment-127.91-52.86-1.91-0.950.00-0.430.00
Common Stock Issued37.5318.16103.900.83244.3361.000.06
Other Financing Activities13.5218.164.450.0044.670.510.00
Net Cash from Financing Activities-90.3771.71129.601.18303.4286.230.27
Summary
Effect of Forex Changes on Cash0.000.000.000.000.000.000.00
Net Change in Cash-96.69-35.07-16.7971.9550.92-20.8149.73
Cash at Beginning of Period136.15171.22188.00116.0565.1385.9336.20
Cash at End of Period39.46136.15171.22188.00116.0565.1385.93
Free Cash Flow-148.99-125.33-238.64-2.88-94.20-77.52-64.79
Supplemental Disclosures
Interest Paid10.8612.554.932.452.450.220.00